M&A Deal Summary

Brooklyn ImmunoTherapeutics Acquires Novellus Therapeutics

On June 14, 2021, Brooklyn ImmunoTherapeutics acquired life science company Novellus Therapeutics from Factor Bioscience for 125M USD

Acquisition Highlights
  • This is Brooklyn ImmunoTherapeutics’ 2nd transaction in the Life Science sector.
  • This is Brooklyn ImmunoTherapeutics’ largest (disclosed) transaction.
  • This is Brooklyn ImmunoTherapeutics’ 3rd transaction in the United States.
  • This is Brooklyn ImmunoTherapeutics’ 1st transaction in Massachusetts.

M&A Deal Summary
Date 2021-06-14
Target Novellus Therapeutics
Sector Life Science
Buyer(s) Brooklyn ImmunoTherapeutics
Sellers(s) Factor Bioscience
Deal Type Divestiture
Deal Value 125M USD

Target

Novellus Therapeutics

Cambridge, Massachusetts, United States
Novellus Therapeutics is a company developing next-generation engineered mesenchymal stem cell therapies using patented mRNA cell reprogramming and gene editing technologies. Novellus Therapeutics was founded in 2015 and is based in Cambridge, Massachusetts.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Brooklyn ImmunoTherapeutics

Brooklyn, New York, United States
Category Company
Sector Life Science
DESCRIPTION

Brooklyn ImmunoTherapeutics is focused on providing cytokine-based therapy to treat patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications. Brooklyn ImmunoTherapeutics is based in Brooklyn, New York.

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 2 of 2
Type (Divestiture) 1 of 1
State (Massachusetts) 1 of 1
Country (United States) 3 of 3
Year (2021) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-08-13 Buzztime

Carlsbad, California, United States

Buzztime delivers interactive entertainment and innovative technology that helps its customers acquire, engage, and retain their patrons. The company's tablets, mobile app, and technology offer engaging solutions to establishments that have guests who experience dwell time, such as in bars, restaurants, casinos, and senior living centers. Buzztime was founded in 1983 and is based in Carlsbad, California.

Buy -

Seller(S) 1

SELLER

Factor Bioscience

Cambridge, Massachusetts, United States
Category Company
Founded 2011
Sector Life Science
DESCRIPTION

Factor Bioscience develops technologies for engineering cells to advance the study and treatment of disease. Factor Bioscience developed the fastest, highest-efficiency method for reprogramming somatic cells to a pluripotent stem-cell state, a key invention now recognized by several patents. This technology, which enables the production of patient-specific cells for transplantation, has wide-ranging applications in personalized regenerative medicine. Factor Bioscience was founded in 2011 and is based in Cambridge, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2021) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal